Medical Research News

RSS

Olive oil produces greater weight loss in breast cancer survivors: Researchers

Researchers from The Miriam Hospital have found that olive oil may offer another potential health benefit - it produces greater weight loss in breast cancer survivors compared to a more traditional low-fat diet.

3 Jun 2010

Discovery provides new therapeutic target to prevent brain function loss

Researchers at Mount Sinai School of Medicine have found that certain types of specializations on nerve cells called "spines" are depleted as a person ages, causing cognitive decline in the part of the brain that mediates the highest levels of learning. These spines receive an important class of synapses that are involved with the process of learning.

3 Jun 2010

Three in five Americans may develop noise-induced hearing loss

Use of ear bud headphones by youngsters may save your ears from being assaulted by the noise of your teenagers' music or electronic game but are they damaging your child's hearing?

3 Jun 2010

Protein-rich breakfast may reduce calorie consumption

According to a report in the Journal of the American Medical Association, nearly one in three American children are overweight or obese, which increases their risk for developing obesity-related chronic diseases such as diabetes, high blood pressure, heart disease and cancer.

3 Jun 2010

Chocolate milk offers recovery advantage to help repair and rebuild muscles: Researchers

One of the best post-exercise recovery drinks could already be in your refrigerator, according to new research presented at the American College of Sports Medicine conference this week. In a series of four studies, researchers found that chocolate milk offered a recovery advantage to help repair and rebuild muscles, compared to specially designed carbohydrate sports drinks.

3 Jun 2010

Novel anti-malarial drug developed from blood thinner by Australian scientists

Malaria caused by a parasite that is borne in female mosquitoes and that spreads in humans through mosquito bites is a major public health problem and it kills more than a million people world wide each year. With the rise of resistance of many of the strains of the malaria parasite to most of the anti-malarial drugs the problem is escalating at an alarming pace.

2 Jun 2010

Chronix Biomedical to launch new disease detection, monitoring service for cancer researchers at 2010 ASCO

Chronix Biomedical today announced that it will launch a new disease detection and monitoring service for cancer researchers at the upcoming 2010 ASCO Annual Meeting. The "For Investigational Use Only" laboratory-based testing service uses Chronix's breakthrough approach—the Chronix Apoptotic DNA Blood Test—which analyzes apoptotic DNA from dead and dying cells to identify and track ongoing changes associated with specific cancers and other chronic diseases.

2 Jun 2010

Research findings advance the effort to develop AIDS vaccine

In findings that contribute to efforts to design an AIDS vaccine, a team led by Scripps Research Institute scientists has determined the structure of an immune system antibody molecule that effectively acts against most strains of human immunodeficiency virus, the virus that causes AIDS.

2 Jun 2010

Illumina commences shipment of new HumanOmni2.5-Quad DNA Analysis BeadChip microarray

Illumina, Inc. today announced that it has begun shipping its new HumanOmni2.5-Quad DNA Analysis BeadChip (Omni2.5). This microarray contains millions of newly discovered genome-wide common and rare variants from the 1,000 Genomes Project (1kGP), selected to maximize its ability to detect new associations.

From Illumina, Inc. 2 Jun 2010

LAB Research's Canadian laboratory receives OECD-GLP compliance status

LAB Research Inc., a Canadian-based global non-clinical contract research organization, today announced that its Canadian laboratory has received a Good Laboratory Practices recognition from the Standards Council of Canada.

2 Jun 2010

Heart attack patients treated beyond maximum recommended time have increased mortality: Study

An examination of the treatment received by patients with myocardial infarction (heart attack) at 80 hospitals in Quebec indicates that those who received either primary percutaneous coronary intervention (PPCI; such as angioplasty) or fibrinolysis (administration of medication to dissolve blood clots) beyond the times recommended in international guidelines had a significantly increased risk of death within 30 days, along with an increased risk of the combined outcome of death or readmission for heart attack or heart failure at one year, according to a study in the June 2 issue of JAMA.

2 Jun 2010

GMC to participate in ProTECT III study of progesterone for emergency treatment of TBI

Geisinger Medical Center will participate in ProTECT III, a groundbreaking National Institute of Health -sponsored research study for the emergency treatment of traumatic brain injuries using the hormone progesterone.

2 Jun 2010

CDRD, Vancouver Prostate Centre announce preferred collaboration agreement

The Centre for Drug Research and Development (CDRD) and the Vancouver Prostate Centre (VPC) today announced that they have signed a preferred collaboration agreement as the two organizations jointly strive to accelerate the discovery, development and commercialization of anti-cancer therapeutics.

2 Jun 2010

Majority of poker players use performance enhancing drugs: Study

A Nova Southeastern University study recently presented at a national conference found that 80 percent of poker players around the world reported using drugs and other substances to enhance their performance in poker.

2 Jun 2010

TQ can suppress growth of aggressive PCa cell lines: Researchers

Researchers at the Tulane University School of Medicine, in New Orleans, LA, have demonstrated that thymoquinone a major component of black seed oil (Nigella sativa) can suppress the growth of several aggressive prostate cancer cell lines, in vitro. Although previous studies have shown the anti-proliferative effects of TQ in different types of cancers, the molecular mechanism of this effect of TQ had not been delineated.

2 Jun 2010

AFFiRiS to explore ProBioGen's HuALN technology for AFFITOME-based vaccination concept

AFFiRiS AG will explore ProBioGen's proprietary Human Artificial Lymph Node Technology (HuALN) as analytical tool for its AFFITOME®-based vaccination concept. Under the contract with ProBioGen, AFFiRiS will evaluate the HuALN technology as a human organoid model to investigate drug-related effects in the context of the human immune system in order to select vaccine candidates best suited to be applied in humans.

2 Jun 2010

University of Minnesota, Mayo Clinic form strategic research relationship with Karolinska Institute

The University of Minnesota and Mayo Clinic, under the mantle of the Minnesota Partnership for Biotechnology and Medical Genomics, have formed a strategic research relationship with the Karolinska Institute of Stockholm, Sweden, the top-rated medical research university in Europe. Leaders of each institution signed memoranda of understanding to commit to the formal ongoing collaboration, called the Frontiers of Biomedical Research.

2 Jun 2010

New research project to discover origin of myelodysplasia

The University of Navarra, together with the University of Oxford and three other European centres, are taking part in a project to discover the origin of myelodysplasia, an ailment with a predisposition to develop into leukaemia. In the work, patients from 19 hospitals in the north of Spain - including the University Hospital of Navarra - were analysed, as well as from England, Italy, Sweden and Germany.

2 Jun 2010

Men who refuse surgery for prostate cancer have 51% overall survival rate: Study

Men who refuse surgery for prostate cancer and instead opt for "watchful waiting" - monitoring cancer progression without undergoing treatment - have a significantly worse long-term survival rate than those patients that choose radiotherapy, according to researchers at Henry Ford Hospital in Detroit.

2 Jun 2010

Texas A&M uses pGAP and IBM supercomputing technology to boost tuberculosis research

IBM today announced that Texas A&M University used IBM supercomputing technology to carry out potentially life-saving tuberculosis research at a rate more than four times faster than was previously possible.

2 Jun 2010

Medical Research News

Olive oil produces greater weight loss in breast cancer survivors: Researchers

Discovery provides new therapeutic target to prevent brain function loss

Three in five Americans may develop noise-induced hearing loss

Protein-rich breakfast may reduce calorie consumption

Chocolate milk offers recovery advantage to help repair and rebuild muscles: Researchers

Novel anti-malarial drug developed from blood thinner by Australian scientists

Chronix Biomedical to launch new disease detection, monitoring service for cancer researchers at 2010 ASCO

Research findings advance the effort to develop AIDS vaccine

Illumina commences shipment of new HumanOmni2.5-Quad DNA Analysis BeadChip microarray

LAB Research's Canadian laboratory receives OECD-GLP compliance status

Heart attack patients treated beyond maximum recommended time have increased mortality: Study

GMC to participate in ProTECT III study of progesterone for emergency treatment of TBI

CDRD, Vancouver Prostate Centre announce preferred collaboration agreement

Majority of poker players use performance enhancing drugs: Study

TQ can suppress growth of aggressive PCa cell lines: Researchers

AFFiRiS to explore ProBioGen's HuALN technology for AFFITOME-based vaccination concept

University of Minnesota, Mayo Clinic form strategic research relationship with Karolinska Institute

New research project to discover origin of myelodysplasia

Men who refuse surgery for prostate cancer have 51% overall survival rate: Study

Texas A&M uses pGAP and IBM supercomputing technology to boost tuberculosis research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News